Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):991-995; doi:10.1093/jnci/djm056
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/13/991    most recent
djm056v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

ANGIOGENESIS UPENDED

Targeting Vessel Abnormalization in Cancer

Ken Garber

The first 150 words of the full text of this article appear below.

The role of angiogenesis in cancer is now so well accepted that it's easy to forget how young the field is. New discoveries still have the power to change how people think about blood vessels and cancer. The latest example: deltalike ligand 4 (DLL4).

DLL4 is generating intense interest because it offers a new way to use angiogenesis, or new blood vessel formation, against tumors. At least three biotech companies are now racing each other to be first in the clinic with a DLL4-blocking drug, a milestone that will probably come sometime next year. Activity "has really heated up," said Jan Kitajewski, Ph.D., a cancer researcher at Columbia University in New York.

One reason for the buzz is DLL4's link to vascular endothelial growth factor (VEGF). VEGF is thought to be the dominant growth factor driving angiogenesis in cancer; bevacizumab (Avastin), Genentech's FDA-approved colorectal and lung cancer drug, targets VEGF. . . . [Full Text of this Article]

Bad Vessels Grow, Tumors Slow?

Rethinking Angiogenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Notch Emerges as New Cancer Drug Target
Ken Garber
J Natl Cancer Inst 2007 99: 1284-1285. [Extract] [Full Text] [PDF]